partnershipMainz Biomed Partners with Microba Life Sc...Molecular diagnostics specialist Mainz Biomed NV has inked a research collaboration with precision microbiome firm Microba Life Sciences Inc. more ➔
financingDiogenX SA raises €27.5M in Series A fin... French pancreatic beta-cell modulator specialist DiogenX SA has raised €27.5m in a Series A financing led by Boehringer Ingelheim Venture Fund and Roche Venture Fund. more ➔
M&AWacker AG expands biotech business through...Munich-based Wacker Group has purchased all shares of the Spanish CMO ADL BioPharma from financial investor Kartesia for €100m. more ➔
partnershipNeogap Therapeutics AB partners with Celle...Swedish AI specialist Neogap Therapeutics AB will secect antigens for Cellerys AG, which wants to establish immune tolerance in a Phase II MS trial. more ➔
CDMODutch State to sell share capital of Intra...The State of the Netherlands, and the Dutch Ministry of Health, Welfare and Sport will sell all shares of vaccine maker Intravacc B.V. more ➔
partnershipTay Therapeutics in licensing deal with VY...Tay Therapeutics Ltd announces licencing of its oral BET blocker TayB2 to VYNE Therapeutics Inc as a treatment for immuno-inflammatory and fibrotic disorders. more ➔
Medigene licences CD40L-CD28 costimulatory...German Medigene AG has acquired global rights to the CD40L-CD28 costimulatory switch receptor that modulates the tumour stroma in order to make T-TCR therapies more effective. more ➔
EU to decarbonise aviation sector through...The European Commission has proposed to set binding sustainable aviation fuels (SAF) targets for the aviation sector to incentivise demand for and supply of SAF vs. kerosene. more ➔
Swiss Biotech Report: Sunrise, not sunset,...In 2022, the Swiss biotech industry "continued to demonstrate its resilience, adapting well to geopolitical upheavals and remaining a key driver of innovation for global healthcare". Swiss … more ➔
Novartis in US$465m deal with 3B Pharmaceu...Targeted radiopharmaceuticals maker 3B Pharmaceuticals snaps US$40m upfront in a global exclusive licensing agreement for its FAP-Targeting Peptide Technology. more ➔
